(vianews) - the market ended the session with erytech pharma (eryp.pa) rising 12.52% to €0.89 on thursday while cac 40 rose 0.11% to €7,139.25.
erytech pharma's last close was €0.80, 64.82% under its 52-week high of €2.26.
about erytech pharma
erytech pharma s.a., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in france and the united states. its lead product candidate is eryaspase, which is in phase 3 clinical development for the treatment of second-line pancreatic cancer, and in phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. the company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. the company was incorporated in 2004 and is headquartered in lyon, france.
earnings per share
as for profitability, erytech pharma has a trailing twelve months eps of €-1.14.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, erytech pharma's stock is considered to be oversold (<=20).
yearly top and bottom value
erytech pharma's stock is valued at €0.89 at 21:32 est, way under its 52-week high of €2.26 and way higher than its 52-week low of €0.29.
moving average
erytech pharma's worth is way above its 50-day moving average of €0.65 and higher than its 200-day moving average of €0.85.more news about erytech pharma (eryp.pa).